Cangrelor: Safe and Effective for Left Ventricular Assist Device Thrombosis
The VAD Journal · 2020
DOI: 10.11589/vad/e2020621 ↗Kurz gefasst
Fachartikel in der Zeitschrift The VAD Journal, 2020. Verfasst von Roopa Rao und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Pump thrombosis is a devastating complication of left ventricular assist device implantation as it increases the risk of mortality and morbidity. Early and effective treatment is important to prevent the progression of the clot and to avoid the surgical need for pump exchange or heart transplant. The current strategies of intensifying anticoagulation therapy are not consistently effective and carry significant bleeding risks. Cangrelor is a new pharmacological agent that has been utilized as an antiplatelet agent in several cardiac procedures. In this case series, we describe the use of cangrelor for left ventricular assist device thrombosis in five patients. Cangrelor appears to be a potentially safe and effective alternative strategy.
Zitieren
APA
Rao, R., Anderson, E., Jones, M., Safiia, M., & Guglin, M. (2020). Cangrelor: Safe and Effective for Left Ventricular Assist Device Thrombosis. The VAD Journal. https://doi.org/10.11589/vad/e2020621
Vancouver
Rao R, Anderson E, Jones M, Safiia M, Guglin M. Cangrelor: Safe and Effective for Left Ventricular Assist Device Thrombosis. The VAD Journal. 2020. doi:10.11589/vad/e2020621
BibTeX
@article{Rao2020,
author = {Rao, Roopa and Anderson, Eve and Jones, Mark and Safiia, Muhamed and Guglin, Maya},
title = {Cangrelor: Safe and Effective for Left Ventricular Assist Device Thrombosis},
journal = {The VAD Journal},
year = {2020},
doi = {10.11589/vad/e2020621}
}
EUVIMED